Literature DB >> 147116

Fast-acting plasmin inhibitor in human plasma.

D Collen, B Wiman.   

Abstract

The fast-acting and physiologically most important inhibitor of plasmin in human plasma is a recently discovered and purified alpha 2-glycoprotein with a molecular weight of 65,000-70,000 daltons occurring at a concentration of 1 muM. The inhibitor rapidly forms a completely inactive 1:1 stoichometric complex with plasmin through reaction with the B chain (light chain) of the enzyme, which contains the active center. It also reacts with trypsin and very slowly with urokinase and with some other enzymes in purified systems, but its role in vivo as an inhibitor of proteases other than plasmin seems negligible. Antiplasmin is the only plasma protein that can inhibit the fibrinolysis associated with transformed or malignant cells. The plasmin-antiplasmin complex contains neoantigenic structures not present in the parent molecules that may form the basis of immunochemical methods for detecting activation of the fibrinolvtic system in blood.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 147116

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  14 in total

1.  Amorphous protein aggregates stimulate plasminogen activation, leading to release of cytotoxic fragments that are clients for extracellular chaperones.

Authors:  Patrick Constantinescu; Rebecca A Brown; Amy R Wyatt; Marie Ranson; Mark R Wilson
Journal:  J Biol Chem       Date:  2017-07-14       Impact factor: 5.157

2.  alpha 2-Antiplasmin Enschede: dysfunctional alpha 2-antiplasmin molecule associated with an autosomal recessive hemorrhagic disorder.

Authors:  C Kluft; H K Nieuwenhuis; D C Rijken; E Groeneveld; G Wijngaards; W van Berkel; G Dooijewaard; J J Sixma
Journal:  J Clin Invest       Date:  1987-11       Impact factor: 14.808

3.  Comparison of plasmin with recombinant tissue-type plasminogen activator in lysis of cerebral thromboemboli retrieved from patients with acute ischemic stroke.

Authors:  Victor J Marder; Ales Blinc; Theresa Gruber; Gregor Tratar; Miso Sabovic; Sidney Starkman; Reza Jahan; Gary Duckwiler; Fernando Vinuela; Satoshi Tateshima; David Liebeskind; Bruce Ovbiagele; Letisha Ali; Doojin Kim; Nestor Gonzalez; Paul M Vespa; Jeffrey L Saver
Journal:  Stroke       Date:  2011-06-23       Impact factor: 7.914

4.  Structural studies of human IgD: isolation by a two-step purification procedure and characterization by chemical and enzymatic fragmentation.

Authors:  L C Lin; F W Putnam
Journal:  Proc Natl Acad Sci U S A       Date:  1979-12       Impact factor: 11.205

5.  Matrix Metalloproteinase-9 Mediates the Deleterious Effects of α2-Antiplasmin on Blood-Brain Barrier Breakdown and Ischemic Brain Injury in Experimental Stroke.

Authors:  Satish Singh; Aiilyan K Houng; Guy L Reed
Journal:  Neuroscience       Date:  2017-12-30       Impact factor: 3.590

6.  Concentration of plasminogen and antiplasmin in plasma and serum.

Authors:  S A Cederholm-Williams
Journal:  J Clin Pathol       Date:  1981-09       Impact factor: 3.411

7.  Affinity-chromatographic purification of human alpha 2-antiplasmin.

Authors:  B Wiman
Journal:  Biochem J       Date:  1980-10-01       Impact factor: 3.857

8.  A lysine-binding protein in SLE sera inhibits the binding of immune complexes to normal erythrocyte CR1 (complement receptor type 1).

Authors:  Y C Ng; D K Peters; S A Cederholm-Williams; M J Walport
Journal:  Clin Exp Immunol       Date:  1987-07       Impact factor: 4.330

9.  Synthesis and secretion of alpha 2-plasmin inhibitor by established human liver cell lines.

Authors:  H Saito; L T Goodnough; B B Knowles; D P Aden
Journal:  Proc Natl Acad Sci U S A       Date:  1982-09       Impact factor: 11.205

10.  Significance of cross-linking of alpha 2-plasmin inhibitor to fibrin in inhibition of fibrinolysis and in hemostasis.

Authors:  Y Sakata; N Aoki
Journal:  J Clin Invest       Date:  1982-03       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.